Table 2.
Main trials of conversion chemotherapy.
| Study | Year | n | Study Population | Treatment | RR | Liver Resection Rate |
|---|---|---|---|---|---|---|
| CELIM [25] | 2010 | 106 | No molecular selection | FOLFOX6/FOLFIRI + Cet | All patients: 63% KRAS ex2wt: 70% |
33% |
| GONO [26] | 2010 | 30 | No molecular selection | FOLFOXIRI + Bev | 80% | 40% |
| BOXER [27] | 2011 | 46 | No molecular selection | CAPOX + Bev | 78% | 40% |
| Ye et al. [23] | 2013 | 138 | KRAS exon 2 wild-type | FOLFIRI/FOLFOX ± Bev | 57% vs. 29% | 26% vs. 7% |
| OLIVIA [28] | 2015 | 80 | No molecular selection | FOLFOXIRI + Bev vs. FOLFOX + Bev | 81% vs. 62% | 49% vs. 23% |
| PLANET-TTD [24] | 2017 | 77 | KRAS exon 2 wild type | FOLFOX + Pmab vs. FOLFIRI + Pmab | 74% vs. 67% | 34% vs. 46% |
| VOLFI [29] | 2019 | 99 | KRAS exon 2 wild type. Other RAS mutations included but excluded from the analysis | FOLFOXIRI + Pmab vs. FOLFOXIRI | 87.3% vs. 60.6% | Global population: 33.3% vs. 12.1% Convertible population: 75% vs. 36.4%. |
Abbreviations: Bev—bevacizumab, CAPOX—capecitabine + oxaliplatin, Cet—cetuximab, FOLFIRI—5-FU + irinotecan, FOLFOX—5-FU + oxaliplatin, FOLFOXIRI—5-FU + oxaliplatin + irinotecan, n—number of patients, Pmab—panitumumab, RR—resection rate.